Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: Prevalence, course of severity, and quality of life correlates
Authors:
- Johannes Maria GiesingerJGJohannes Maria Giesinger
- Anne OberguggenbergerAOAnne Oberguggenberger
- Georg KemmlerGKGeorg Kemmler
- Lisa Maria WintnerLWLisa Maria Wintner
- Klaus GattringerKGKlaus Gattringer
- Barbara Sperner-UnterwegerBSBarbara Sperner-Unterweger
- Bernhard HolznerBHBernhard Holzner
- August ZaberniggAZAugust Zabernigg
- 30 November 2011
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 51 (4) , 490-496
Abstract
Background. Taste alterations (TAs) are frequently reported by chemotherapy patients. However, research on this topic is very scarce. The etiologies of TAs are not fully known and prevalences may vary across tumour types and chemotherapy regimens. The aim of the present study was to longitudinally investigate TAs in patients with breast cancer or gynaecological cancers receiving chemotherapy, and to provide expected values for TAs for these patient populations. Patients and methods. One hundred and nine cancer patients (32.1% gynaecological cancer, 67.9% breast cancer) receiving chemotherapy at the Department for Internal Medicine of Kufstein County Hospital were consecutively included in the study. At each visit the Quality of Life Questionnaire-Core30 and a screening scale for TAs, consisting of two validated questions taken from the European Organisation for Research and Treatment of Cancer item bank was administered. Statistical analysis was performed using mixed-effect models. Results. The prevalence of TAs in breast cancer and gynaecological cancer patients receiving chemotherapy was high (76.1%). There were differences in the extent of TAs as well as in their time course across treatment groups. The lowest TAs were found in breast cancer and gynaecological cancer patients treated with gemcitabine. The highest TAs were found in breast cancer patients treated with epirubicin/docetaxel/capecitabine. The steepest increase of TAs was found in patients treated with epirubicin/docetaxel. Moreover, significant associations between TAs and appetite loss as well as fatigue were found. Conclusion. The results show that TAs are an issue in breast and gynaecological cancer patients receiving different chemotherapy regimens. There is a need for a more systematic investigation of TAs in chemotherapy patients in general as well as the need to address this issue in clinical practice.Keywords
This publication has 28 references indexed in Scilit:
- Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)Breast Cancer Research and Treatment, 2011
- Taste Alterations in Cancer Patients Receiving Chemotherapy: A Neglected Side Effect?The Oncologist, 2010
- Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: a cohort studyBMC Cancer, 2010
- Influence of taste disorders on dietary behaviors in cancer patients under chemotherapyNutrition Journal, 2010
- Health related quality of life in a nationally representative sample of haematological patientsEuropean Journal of Haematology, 2009
- Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast CancerBreast Cancer Research and Treatment, 2006
- Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of EpirubicinThe Oncologist, 2005
- Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian CancerGynecologic Oncology, 2002
- Lipid Peroxides in the Polychemotherapy of Cancer PatientsChemotherapy, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993